This order is for a stably PD1-transfected CHO cell line that we will be using as a positive control for in experiments where we will carefully test, select, and optimize appropriate reagents and…

Ended Awarded Last action

Contract number
HHSN26800002
Awardee
Awarding agency
Obligated
$8,535

Award facts

Contract value 100% obligated
$8,534.98 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
621991 Blood and Organ Banks
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Piscataway, NJ 08854, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00001 · Contract closeout. -$0
Original award $8,535

Description

As the agency reported it.

This order is for a stably PD1-transfected CHO cell line that we will be using as a positive control for in experiments where we will carefully test, select, and optimize appropriate reagents and antibodies so that we can generate robust, reliable, and publishable data genscript USA incorporated:1171214 [16-011472]

Quick answers

Who was awarded contract HHSN26800002?

HHSN26800002 was awarded to Genscript USA Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on March 22, 2016.

How much is contract HHSN26800002 worth?

The government has obligated $8,535 on HHSN26800002.

Is contract HHSN26800002 an order under another contract?

Yes. HHSN26800002 is a BPA call under HHSN263201400039B, a blanket purchase agreement.

Was contract HHSN26800002 competed?

The extent of competition for HHSN26800002 was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login